Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025
Tandem Diabetes Care (TNDM), a leading insulin delivery and diabetes technology company, has scheduled its first quarter 2025 financial results announcement for April 30, 2025, after market close.
The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss Q1 2025 financial and operating results. Investors can access the live webcast through Tandem's Investor Center website, and a recording will be available for 30 days afterward.
Tandem Diabetes Care (TNDM), un'azienda leader nella consegna di insulina e nella tecnologia per il diabete, ha programmato l'annuncio dei suoi risultati finanziari del primo trimestre 2025 per 30 aprile 2025, dopo la chiusura del mercato.
L'azienda ospiterà una conference call e un webcast simultaneo alle 4:30 PM ora orientale (1:30 PM ora del Pacifico) per discutere i risultati finanziari e operativi del Q1 2025. Gli investitori possono accedere al webcast dal vivo attraverso il sito web del Centro Investitori di Tandem, e una registrazione sarà disponibile per 30 giorni dopo.
Tandem Diabetes Care (TNDM), una empresa líder en la entrega de insulina y tecnología para la diabetes, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 30 de abril de 2025, después del cierre del mercado.
La empresa llevará a cabo una llamada de conferencia y un webcast simultáneo a las 4:30 PM hora del Este (1:30 PM hora del Pacífico) para discutir los resultados financieros y operativos del Q1 2025. Los inversores pueden acceder al webcast en vivo a través del sitio web del Centro de Inversores de Tandem, y una grabación estará disponible durante 30 días después.
탄뎀 다이아베티스 케어 (TNDM), 인슐린 전달 및 당뇨병 기술 분야의 선두 기업이 2025년 1분기 재무 결과 발표를 2025년 4월 30일, 시장 마감 후로 예정했습니다.
회사는 동부 표준시 기준 오후 4시 30분 (태평양 표준시 기준 오후 1시 30분)에 2025년 1분기 재무 및 운영 결과에 대해 논의하기 위해 컨퍼런스 콜과 동시 웹캐스트를 개최할 것입니다. 투자자들은 탄뎀의 투자자 센터 웹사이트를 통해 라이브 웹캐스트에 접속할 수 있으며, 녹화본은 이후 30일 동안 이용 가능합니다.
Tandem Diabetes Care (TNDM), une entreprise leader dans la livraison d'insuline et la technologie du diabète, a prévu l'annonce de ses résultats financiers du premier trimestre 2025 pour le 30 avril 2025, après la fermeture des marchés.
L'entreprise organisera une conférence téléphonique et un webinaire simultané à 16h30 heure de l'Est (13h30 heure du Pacifique) pour discuter des résultats financiers et opérationnels du T1 2025. Les investisseurs peuvent accéder au webinaire en direct via le site web du Centre des investisseurs de Tandem, et un enregistrement sera disponible pendant 30 jours après.
Tandem Diabetes Care (TNDM), ein führendes Unternehmen für Insulinabgabe und Diabetes-Technologie, hat die Bekanntgabe seiner Finanzergebnisse für das erste Quartal 2025 für den 30. April 2025 nach Börsenschluss angesetzt.
Das Unternehmen wird um 16:30 Uhr Eastern Time (13:30 Uhr Pacific Time) eine Telefonkonferenz und einen gleichzeitigen Webcast abhalten, um die finanziellen und operativen Ergebnisse des Q1 2025 zu erörtern. Investoren können über die Website des Investor Centers von Tandem auf den Live-Webcast zugreifen, und eine Aufzeichnung wird 30 Tage lang verfügbar sein.
- None.
- None.
A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI72222fa42d1c492fb004c1b47dbaf791) and you will be provided with dial-in details, including a personal pin.
An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in
Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403373066/en/
Media Contact:
858-366-6900
media@tandemdiabetes.com
Investor Contact:
858-366-6900
IR@tandemdiabetes.com
Source: Tandem Diabetes Care, Inc.
FAQ
When will Tandem Diabetes Care (TNDM) release Q1 2025 earnings?
What time is TNDM's Q1 2025 earnings conference call?
How can investors access TNDM's Q1 2025 earnings call?
How long will TNDM's Q1 2025 earnings webcast recording be available?
